Study: Kavanagh 2022, JAMA
Sickle Cell Disease: A Review
Citation
Kavanagh PL, Fasipe TA, Wun T (2022). JAMA. PubMed id 35788790.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Sickle cell disease: what it is, treatment and newborn screening Tier B thin
B Adults and children with sickle cell disease, mainly in the US, plus worldwide figures (n=not applicable)
Narrative review (JAMA).
About 300,000 infants a year are born with sickle cell disease worldwide, most living in sub-Saharan Africa, India, the Mediterranean and the Middle East; about 100,000 people have it in the US. Diagnosis is by newborn screening where available. In the US nearly all children survive to adulthood, but average life expectancy remains about 20 years less than the general population. Hydroxyurea is first-line therapy for most people; stem cell transplant is the only curative therapy, limited by donor availability.
As recorded in this card: Kavanagh PL, Fasipe TA, Wun T (2022), JAMA, [review]
Note: Review, mostly US data; the 20-year figure is a US figure.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.